Results 321 to 330 of about 584,539 (379)

C‑Nucleosides Stabilize RNA by Reducing Nucleophilicity at 2'-OH. [PDF]

ACS Cent Sci
Banerjee D, Xiao L, Thacker PS, Kundu J, Manoharan M, Kool ET.   +5 more
europepmc   +1 more source

G4 Oligonucleotide-Based Chaperones of Heterogeneous Nuclear Ribonucleoprotein A1. [PDF]

Int J Mol Sci
Malakhova E, Svetlova J, Pavlova I, Alieva S, Severov V, Barinov N, Klinov D, Vedekhina T, Varizhuk A.   +8 more
europepmc   +1 more source

High-resolution HIV-1 m⁶A epitranscriptome reveals isoform-dependent methylation clusters and unique 2-LTR transcript modifications. [PDF]

NAR Genom Bioinform
Naquin D, Blanchet S, van Dijk E, Bertrand L, Grégoire S, Ramirez BC, Ouazahrou R, Jaszczyszyn Y, Moris A, Thermes C, Hernandez C, Namy O.   +11 more
europepmc   +1 more source

Potentially prebiotic isocyanide activation chemistry drives RNA assembly.

Chem Commun (Camb)
Zhang SJ, Jia X, DasGupta S, Szostak JW.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antisense Oligonucleotides

Nephron Experimental Nephrology, 1998
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire   +2 more sources

Therapeutic Oligonucleotides: State of the Art.

Annual Review of Pharmacology and Toxicology, 2019
Oligonucleotides (ONs) can interfere with biomolecules representing the entire extended central dogma. Antisense gapmer, steric block, splice-switching ONs, and short interfering RNA drugs have been successfully developed.
C. I. E. Smith, R. Zain
semanticscholar   +1 more source

Treating Disease at the RNA Level with Oligonucleotides.

New England Journal of Medicine, 2019
Oligonucleotides in Drug Development As research on the structure and function of RNAs has rapidly expanded, so too has the number of oligonucleotide drugs in clinical development that regulate RNA...
A. Levin
semanticscholar   +1 more source

Oligonucleotidic therapeutics

Expert Opinion on Drug Discovery, 2008
Numerous oligonucleotide-based biopharmaceuticals have been tested to suppress disease progression. These potent therapeutics include plasmids containing transgenes, antisense oligonucleotides, ribozymes, DNAzymes, decoys, aptamers and small interfering RNAs.
Yoshitaka, Isaka, Enyu, Imai, Shiro, Takahara, Hiromi, Rakugi   +3 more
openaire   +2 more sources

Oligonucleotide Charge Reversal: 2′-O-Lysylaminohexyl Modified Oligonucleotides

Nucleosides, Nucleotides & Nucleic Acids, 2007
A novel cationic building nucleoside building block designed for antisense and siRNA oligonucleotides is presented. Protected L-lysine was coupled to 2'-O-aminohexyluridine and the resulting nucleoside was phosphitylated for automated oligonucleotide synthesis.
Winkler, Johannes, Noe, Christian
openaire   +3 more sources